Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Microfabricated engineered particle systems for respiratory drug delivery and other pharmaceutical applications.

Garcia A, Mack P, Williams S, Fromen C, Shen T, Tully J, Pillai J, Kuehl P, Napier M, Desimone JM, Maynor BW.

J Drug Deliv. 2012;2012:941243. doi: 10.1155/2012/941243. Epub 2012 Feb 9.

2.

Future of the particle replication in nonwetting templates (PRINT) technology.

Xu J, Wong DH, Byrne JD, Chen K, Bowerman C, DeSimone JM.

Angew Chem Int Ed Engl. 2013 Jun 24;52(26):6580-9. doi: 10.1002/anie.201209145. Epub 2013 May 13. Review.

3.

Co-opting Moore's law: Therapeutics, vaccines and interfacially active particles manufactured via PRINT®.

DeSimone JM.

J Control Release. 2016 Oct 28;240:541-543. doi: 10.1016/j.jconrel.2016.07.019. Epub 2016 Jul 14.

PMID:
27423326
4.

Formulation Design of Dry Powders for Inhalation.

Weers JG, Miller DP.

J Pharm Sci. 2015 Oct;104(10):3259-88. doi: 10.1002/jps.24574. Epub 2015 Aug 21. Review.

PMID:
26296055
5.

Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation.

Wu X, Hayes D Jr, Zwischenberger JB, Kuhn RJ, Mansour HM.

Drug Des Devel Ther. 2013;7:59-72. doi: 10.2147/DDDT.S40166. Epub 2013 Feb 4.

6.

Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs.

Miller DP, Tan T, Tarara TE, Nakamura J, Malcolmson RJ, Weers JG.

Mol Pharm. 2015 Aug 3;12(8):2582-93. doi: 10.1021/acs.molpharmaceut.5b00147. Epub 2015 Jun 30.

PMID:
26052676
7.

Nanoparticles in the pharmaceutical industry and the use of supercritical fluid technologies for nanoparticle production.

Sheth P, Sandhu H, Singhal D, Malick W, Shah N, Kislalioglu MS.

Curr Drug Deliv. 2012 May;9(3):269-84. Review.

PMID:
22283656
8.

Supercritical Fluid Particle Design of DPI Formulations (Review).

Sun Y.

Curr Pharm Des. 2015;21(19):2516-42. Review.

PMID:
25876911
9.

The role of particle properties in pharmaceutical powder inhalation formulations.

Chew NY, Chan HK.

J Aerosol Med. 2002 Fall;15(3):325-30. Review.

PMID:
12396421
10.

Development of dry powder inhalers.

Chougule MB, Padhi BK, Jinturkar KA, Misra A.

Recent Pat Drug Deliv Formul. 2007;1(1):11-21. Review.

PMID:
19075871
11.

Dry powder aerosol delivery systems: current and future research directions.

Chan HK.

J Aerosol Med. 2006 Spring;19(1):21-7. Review.

PMID:
16551211
12.

Development of budesonide nanocluster dry powder aerosols: processing.

El-Gendy N, Selvam P, Soni P, Berkland C.

J Pharm Sci. 2012 Sep;101(9):3425-33. doi: 10.1002/jps.23168. Epub 2012 Apr 26.

PMID:
22539360
13.

Pulmonary drug delivery by powder aerosols.

Yang MY, Chan JG, Chan HK.

J Control Release. 2014 Nov 10;193:228-40. doi: 10.1016/j.jconrel.2014.04.055. Epub 2014 May 9. Review.

PMID:
24818765
14.
15.
16.

Formulation strategy and use of excipients in pulmonary drug delivery.

Pilcer G, Amighi K.

Int J Pharm. 2010 Jun 15;392(1-2):1-19. doi: 10.1016/j.ijpharm.2010.03.017. Epub 2010 Mar 17. Review.

PMID:
20223286
17.
18.

Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer.

Meenach SA, Anderson KW, Zach Hilt J, McGarry RC, Mansour HM.

Eur J Pharm Sci. 2013 Jul 16;49(4):699-711. doi: 10.1016/j.ejps.2013.05.012. Epub 2013 May 23.

PMID:
23707466
19.

The PulmoSphereâ„¢ platform for pulmonary drug delivery.

Weers J, Tarara T.

Ther Deliv. 2014 Mar;5(3):277-95. doi: 10.4155/tde.14.3. Review.

PMID:
24592954
20.

Supplemental Content

Support Center